Compare GLP-1 Programs, Clinics & Peptide Treatments

Best Semaglutide Providers Online

Ranked by intake process, pricing clarity, support, and medication access.

Best Online Weight-Loss Clinics

Ranked by clinical review, GLP-1 access, support, pricing, and delivery.

GLP-1 Providers

A neutral overview of GLP-1 provider options and next steps.

Semaglutide Providers

Semaglutide provider options and the clinic pathways behind them.

Both are popular online GLP-1 providers, but Eden is usually the simpler starting point while Ro is the more recognisable consumer-health brand.

Eden is the simpler option for most users, while Fridays is better suited to people who want a more support-led programme.

Eden is the stronger all-round starting point, while MEDVi is the more cost-conscious option to benchmark when entry pricing matters most.

Eden is the stronger premium-support starting point, while Shed is better for needle-averse cash-pay users who want a GLP-1 lozenge option and a results guarantee.

Ro is the better fit for users who value a familiar health brand, while Fridays is stronger for users who want more guidance and follow-up structure.

Ro is the more established brand-led option, while MEDVi is the more accessible benchmark when users care more about entry pricing than brand recognition.

Fridays is more support-led, while MEDVi is the simpler affordability comparison for users focused on a lower entry point.

Compare Eden and Strut Health for online GLP-1 and weight-management care.

Compare Gala Health and Embody for online weight-loss and GLP-1 program research.

Compare Hims and Ro for online weight-loss and GLP-1 program research.

Both are Russian-developed peptides registered as medicines in Russia but unapproved in the US and UK. Selank is positioned around anxiety, Semax around cognition and stroke recovery — with evidence bases that largely predate Western-standard trials.

Tirzepatide is an approved, prescribable medicine; retatrutide is still investigational with no approved product anywhere. That access difference — not trial percentages — is the practical distinction for anyone comparing the two today.

Semaglutide is an approved, prescribable medicine available today; cagrilintide is investigational and only exists legitimately inside the CagriSema combination now under FDA review. That access difference — not trial percentages — is the practical distinction in 2026.

Tirzepatide is an approved, prescribable medicine; survodutide is a glucagon/GLP-1 dual agonist still in Phase 3, with approval not projected before 2027. Anyone offered 'survodutide' today is being offered an unapproved product.

Both are common topics in weight-management category pages. Use clinic profiles to compare communication quality, monitoring process, and practical access details.

Semaglutide is associated with weight management pathways while sermorelin appears in hormone optimisation and longevity contexts. Use clinic profiles to compare service scope and clinician oversight.

Tirzepatide targets GLP-1 and GIP receptors for metabolic health while sermorelin is a growth hormone secretagogue used in longevity protocols. Compare clinic listings by treatment focus and governance model.

Both are GLP-1 medications referenced in weight-management listings. Compare provider oversight, monitoring, and access models.

Ozempic and Wegovy are brand names for semaglutide in different clinical contexts. Compare clinic prescribing models and monitoring.

Both topics are often associated with recovery-focused clinic listings. Compare provider transparency, consultation model, and follow-up structure.

Both peptides appear in recovery and regenerative medicine clinic listings. BPC-157 is associated with injury recovery while GHK-Cu is frequently referenced in skin and tissue repair contexts.

TB-500 and GHK-Cu appear in different clinic contexts: recovery pathways versus skin and tissue support. Compare provider focus and monitoring standards.

BPC-157 and ipamorelin appear in different clinic contexts: recovery pathways versus hormone optimisation. Compare provider focus and oversight.

Both are growth hormone secretagogues frequently listed together in clinic protocols. Compare provider transparency, consultation model, and follow-up structure.

Both are growth hormone-releasing peptides used in hormone optimisation and longevity clinic contexts. Compare clinic profiles by protocol transparency and clinician oversight.

Both are referenced as growth hormone secretagogues in performance and longevity clinic listings. MK-677 is orally active while ipamorelin is typically injectable. Compare clinic listings by service scope and monitoring protocols.

HGH and sermorelin are referenced in hormone optimisation and longevity clinic contexts. Compare provider governance, consultation depth, and monitoring standards.

Both appear in hormone optimisation and longevity clinic listings as GH secretagogue options. Compare provider transparency and monitoring protocols.

MK-677 and HGH are referenced in performance and hormone optimisation contexts. Compare clinic governance, prescribing standards, and monitoring.

Sermorelin and tesamorelin are referenced in hormone optimisation contexts. Compare clinic governance and monitoring standards.

Both are referenced in longevity and anti-aging clinic protocols. Compare clinic listings by treatment scope, consultation model, and clinician credentials.

NAD+ and NMN appear in longevity clinic contexts, often with different delivery formats. Compare provider transparency and monitoring.

GHK-Cu and epitalon appear in longevity and regenerative clinic contexts. Compare provider focus, protocol transparency, and oversight.